Abstracts tagged "scleroderma and ulcers"

Abstract Number: 2706 • 2018 ACR/ARHP Annual Meeting
Discriminant Validity and Reliability of World Scleroderma Foundation (WSF) Definition of Skin Ulcers in Systemic Sclerosis
Yossra A Suliman¹, Cosimo Bruni², Sindhu Johnson³, Suzanne Kafaja⁴, Emanuela Praino⁵, Dinesh Khanna⁶, Yannick Allanore⁷, Murray Baron⁸, Jonathan Grotts⁹, Thomas Krieg¹⁰, Ariane L. Herrick¹¹, Christopher P. Denton¹², Marco Matucci-Cerinic¹³ and Daniel E. Furst¹⁴, ¹Rheumatology and Rehabilitation dept., Rheumatology and Rehabilitation dept. Assiut university hospital, Assiut Egypt, Assiut, Egypt, ²Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ³Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁵DIM, Rheumatology Unit - D.E.T.O. - University of Bari (ITALY), Bari, Italy, ⁶Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁷Service de Rhumatologie A, Hôpital Cochin, Paris, France, ⁸Rheumatology, Jewish General Hospital, Montreal, QC, Canada, ⁹Biostatistics, University of California Los Angeles, Los Angeles, CA, ¹⁰Universität zu Köln, Köln, Germany, ¹¹Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ¹²UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ¹³Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: To date, there is lack of a uniform definition of systemic sclerosis related skin ulcer (SSc-skin ulcer) for use in clinical trials. Our group…
Abstract Number: 1871 • 2016 ACR/ARHP Annual Meeting
Predicting Vascular Complications in Systemic Sclerosis: A Prospective Cohort Study
Christopher A. Mecoli¹, Ami A. Shah², Francesco Boin³, Fredrick M. Wigley⁴ and Laura K. Hummers¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, University California San Francisco, San Francisco, CA, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Vascular disease is of fundamental importance in the pathogenesis of scleroderma. Two major vascular complications in scleroderma patients that cause substantial morbidity and mortality…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].